Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MAZE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMaze Therapeutics shareholders elect two directors, ratify auditor at annual meeting
Filed June 10, 2026 · Period ending June 8, 2026 · ~1 min read
Key Changes
-
medium
Shareholders elected Jason Coloma and Neil Kumar as Class I directors to serve until 2029, with 85.8% and 81.6% support respectively (35.8M and 34.1M votes for).
Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR → -
low
Ernst & Young LLP ratified as independent auditor for fiscal 2026 with 99.8% approval (44.6M votes for, 728 against).
Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR → -
low
Annual meeting achieved 89.75% quorum with 44.7M shares present or represented by proxy out of total outstanding shares.
Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR →
Summary
Maze Therapeutics held its 2026 annual meeting on June 8, with shareholders voting on routine governance matters. The meeting achieved a strong 89.75% quorum (44.7 million shares present or by proxy), enabling all agenda items to proceed. Shareholders elected two Class I directors to three-year terms ending in 2029.
Jason Coloma received 35.8 million votes for (85.8% of votes cast) against 5.9 million withheld, while Neil Kumar received 34.1 million for (81.6%) against 7.7 million withheld. Both results reflect healthy approval levels for uncontested director elections. The auditor ratification passed with near-unanimous support at 99.8%. This is a routine annual meeting disclosure with no material governance concerns. The voting outcomes indicate normal shareholder support for management's slate and auditor selection.
Section-by-Section Diff
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
MAZE held its 2026 annual meeting with 89.75% quorum, electing two Class I directors and ratifying Ernst & Young LLP as auditor.
Added in current filing · view on EDGAR → · paraphrased
Jason Coloma, Ph.D.: Votes For 35,792,536, Votes Withheld 5,926,467, Broker Non-Votes 2,941,026; Neil Kumar, Ph.D.: Votes For 34,056,425, Votes Withheld 7,662,578, Broker Non-Votes 2,941,026
Stockholders elected Jason Coloma, Ph.D. and Neil Kumar, Ph.D. as Class I directors to serve until the 2029 annual meeting. Coloma received 85.8% support (35.8M for vs 5.9M withheld) and Kumar received 81.6% support (34.1M for vs 7.7M withheld) of votes cast. Both results represent healthy approval levels for uncontested director elections.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 21, 2026 · How we verify